Benjamin Graham · Investimento deep-value defensivo
Is Arbutus Biopharma Corporation (ABUS) a Benjamin Graham Stock?
Meets only 4/7 Graham criteria, likely overpriced or unstable.
43/100
Não encaixa
4/7 critérios atendidos
Os critérios de Benjamin Graham, aplicados a ABUS
P/E ≤ 15
chave5.1x
P/B ≤ 1.5
chave3.1x
Current ratio ≥ 2
-
Debt / Equity ≤ 1
0.0x
Como ABUS pontua em outras estratégias
Dados financeiros ao vivo
Cap. de mercado
$682.08M
P/L (TTM)
5.1x
ROIC (TTM)
56.72%
Margem bruta
99.98%
Outras análises Benjamin Graham
Perguntas frequentes
What is ABUS's Benjamin Graham fit score?
ABUS scores 43/100 on our Benjamin Graham fit engine. Meets only 4/7 Graham criteria, likely overpriced or unstable.
Does Benjamin Graham actually own ABUS?
Our score is computed from financial fundamentals against Benjamin Graham's published criteria. We don't claim that Benjamin Graham personally owns or recommends ABUS.
How often is this score updated?
ABUS's Benjamin Graham fit score is recomputed daily from the latest TTM financials. The page below shows when it was last refreshed.
Ferramenta educacional, não é consultoria de investimento. As pontuações são calculadas a partir de dados financeiros públicos contra os critérios publicados de cada estratégia de investimento. Não afirmamos que Benjamin Graham possua ou recomende ABUS pessoalmente.
